Abstract Randomized trials have demonstrated the efficacy of radiation and tamoxifen in reducing risk of second events after breast-conserving surgery (BCS) for ductal carcinoma in situ (DCIS), but the comparative effectiveness of mastectomy, BCS, and adjuvant treatments have not been established in community practice. We examined disease-free survival (DFS) among 1,676 DCIS cases diagnosed during 1995-2006 in the population-based Wisconsin In Situ Cohort study. Information on patient and tumor characteristics, treatments, and second breast cancer events were collected via a comprehensive review of data from patient interviews, the statewide cancer registry, and pathology reports. Breast cancer DFS was evaluated according to treatment while adjusting for patient and tumor characteristics. After an average of 7.1 years of follow-up, 143 second breast cancer events occurred. Overall 5-year DFS was similar among women treated with ipsilateral mastectomy (95.6 %; 95 % CI 93.5-97.0) compared to women treated with BCS and radiation (94.8 %; 95 % CI 92.8-96.1), though women receiving BCS without radiation experienced poorer overall DFS (87.0 %; 95 % CI 80.6-91.5). Women treated with tamoxifen in addition to BCS and radiation had a similar risk of a second breast event, although the hazard ratio (HR) suggested a potential benefit (0.70, 95% CI 0.41-1.19). Women treated with BCS, radiation, and tamoxifen had comparable risk of a second event as those treated with ipsilateral mastectomy (HR = 1.20; 95 % CI 0.71-2.02). In this population-based sample, the use of BCS with radiation and tamoxifen resulted in high DFS rates comparable to those achieved by ipsilateral mastectomy.
Introduction
Ductal carcinoma in situ (DCIS) is the earliest detectable form of breast cancer, in which the malignant cells are confined within the basement membrane of the breast ductal system [1] . A dramatic increase in the incidence of DCIS began in the mid-1980s, mirroring the rise in screening mammography [2] . While the incidence of invasive breast cancer has declined over the past decade, diagnoses of DCIS have continued to rise [3] . DCIS now constitutes more than 20 % of all new breast cancers diagnoses, and every year over 60,000 women are diagnosed with DCIS in the United States [4] .
DCIS is considered a true precursor to invasive breast cancer [5] , but the natural history of DCIS is poorly understood [6] . Analyses of SEER registry data suggest that less than 2 % of women with DCIS will die from breast cancer within 10 years of their diagnosis [7] and less than 5 % after about 28 years of follow-up [8] . The high survival rate likely reflects both the availability of effective treatments as well as the relatively indolent nature of most DCIS [9] . Randomized trials have demonstrated that radiation therapy and tamoxifen both improve disease-free survival (DFS) when added to breast-conserving surgery (BCS) [10] [11] [12] [13] . While mastectomy and BCS for DCIS have never been compared in a randomized trial, a meta-analysis of clinic-based observational studies of DCIS diagnosed in 1960s through the early 1990s suggested that local recurrence rates were substantially lower among women treated with mastectomy [14] .
The variation in DFS according to treatment regimens among more recently diagnosed DCIS cases in community practice is much less clear. Substantial changes in DCIS detection, pathology, surgery, and treatment patterns have occurred over the past 15 years [6] . Data from populationbased studies of outcomes after DCIS during this time period are particularly sparse. The Wisconsin In Situ Cohort (WISC) study was designed to evaluate breast cancer outcomes among a large population-based cohort of women newly diagnosed with in situ breast cancer. In this paper, we describe the risk of second breast cancer events among women diagnosed with DCIS between 1995 and 2006. We examined the relative frequency of ipsilateral and contralateral second events, and evaluated DFS among the various treatment groups.
Methods

Study population
The WISC study includes 1,925 women between the ages of 20-74 years with a new first primary diagnosis of DCIS diagnosed during 1995-2006, as reported to the mandatory statewide Wisconsin Cancer Reporting System cancer registry. All such cases were eligible for participation, regardless of the type of facility (academic medical center, community hospital, etc.) in which they were treated. This includes 838 cases who participated in a case-control study [15] during 1997-2001 and 1,087 additional cases recruited during [2002] [2003] [2004] [2005] [2006] . The aim of the case-control study was to compare risk factors for invasive and in situ breast cancer; the purpose of enrolling both waves of DCIS cases was to examine predictors of DFS. Subject eligibility and recruitment has been previously described in detail [16] . In brief, participation was limited to women with known dates of diagnosis, a listed telephone number, and the ability to complete a telephone interview. Eligibility criteria for the parent case-control study and the subsequent cohort study of DCIS cases were the same. Of all eligible cases, 78 % enrolled in the study. All subjects provided verbal informed consent and the study was approved by the University of Wisconsin Health Sciences Institutional Review Board.
Data collection
Baseline and follow-up interviews were conducted to collect patient data [16] . The baseline telephone interview was conducted approximately 1.3 years after diagnosis (interquartile range 1.0-1.5 years). Follow-up interviews began in 2003 and were conducted at approximately 2-year intervals. These interviews were conducted by telephone until 2010 when a mailed survey was used. Overall, 79.7 % of cases completed at least one follow-up interview or survey.
Data on demographics, reproductive history, and cancer screening history were self-reported by participants during these interviews. Treatment history was collected during the baseline interviews beginning in 2002, and a full treatment history was updated for all subjects during follow-up interviews. Treatment information was not collected at baseline interviews for cases who were recruited during 1997-2001 for the case control study; thus, treatment information is missing for these women if they did not complete a follow-up interview (N = 161; Fig. 1 ). Treatment information was missing for an additional 39 women despite participation in an interview in which this information was asked. The cases missing treatment information were slightly older than other participants (mean age 58.3 versus 55.9 years, P \ 0.001) but no other significant differences were observed in demographics, reproductive history, or cancer screening history.
The Wisconsin Cancer Reporting System cancer registry provided pathology data on the baseline DCIS diagnosis, including tumor size, grade, and laterality, as well as date of diagnosis. Data on tumor size and grade were missing for 62 and 48 % of cases, respectively (see Table 1 ).
At each interview, women were asked to report all breast cancer diagnoses since their initial diagnosis. Signed consent was requested from the participants to obtain pathology reports for new diagnoses, and these reports were obtained from the diagnosing hospitals and clinics to confirm these second diagnoses. From these reports, information was collected on laterality and stage (benign, in situ, or invasive diagnosis). A single pathologist reviewed pathology reports to confirm the nature of the diagnosis. Of the 101 self-reported second events for which medical records were available, 92 were confirmed as in situ or invasive (91 %). The nine self-reported second events that were directly contradicted by medical records were not included as second events in this analysis. An additional 42 self-reported second events for which medical records were unavailable were included, for a total of 143 second events. Medical records were unavailable when study subjects refused permission to obtain their pathology reports (consent to this portion of the study was optional) or when the facility was unable or unwilling to disclose the records.
Statistical analysis
We excluded women with missing treatment information (n = 200) and women reporting no treatment beyond biopsy (n = 49), leaving a final sample size of 1,676 (Fig. 1) . Chi-square tests were used to examine whether surgical treatment received varied according to patient and tumor factors. Unadjusted DFS rates for each of these treatment types were estimated using Kaplan-Meier survival estimates with 95 % confidence limits. DFS time in days was defined for each woman as the time from baseline breast cancer diagnosis to date of second event or date of last study contact. For subset analyses, cases with second events missing laterality information (6 %) and/or invasive versus in situ information (29 %) were censored at the time of second event.
All analyses were conducted using SAS statistical software version 9.2. Hazard ratios by surgical treatment, radiation, and tamoxifen status were estimated using Cox proportional hazards regression. Crude models were established with adjustment for age at diagnosis and year of diagnosis only. Multivariable models were additionally adjusted for potentially confounding factors that were selected a priori based on previous literature: menopausal status, screening history, mode of detection, tumor size, grade, and use of raloxifene and aromatase inhibitors. Unknown values of these covariates were estimated with multiple imputation using the Markov Chain Monte Carlo method with ten imputations [17] . The imputation model included all variables listed above from the multivariable model, as well as education level, smoking status, age at first birth, age at menarche, parity, family history of breast cancer, and current use of postmenopausal hormones.
The primary analyses were conducted using the imputed data. Due to the large amount of missing data for tumor size and grade, sensitivity analyses were performed by including only women with complete tumor size and grade information, and by excluding tumor size and grade from the multivariable model. Since BMI may be associated with breast cancer prognosis and may influence treatment decisions, the multivariable analysis was also repeated with adjustment for BMI to assess the impact of this factor.
Results
Selected characteristics of the study sample are summarized by treatment type in Table 1 . The median age of the total study population at the time of diagnosis was 55.1 years, and most women in the study were postmenopausal (58.5 %). About 37 % of subjects reported use of tamoxifen, which was less frequent among women undergoing mastectomy compared to those treated with BCS (P \ 0.001). Approximately 3 % of the study population reported use of raloxifene and 4 % reported use of aromatase inhibitors. Use of BCS increased over time during the study period, while use of mastectomy declined (Fig. 2) . Mastectomy was more frequent among younger, premenopausal women, women whose tumors were detected by a method other than routine mammography, and women with larger or higher grade tumors (Table 1) . Among women treated with BCS, the use of radiation increased modestly over time (Fig. 2) . Tamoxifen use increased substantially during the study period. Of women diagnosed in 1995-1997, 13.2 % used tamoxifen, compared to 46.5 % of women diagnosed in [2004] [2005] [2006] (Fig. 2) .
Over an average of 7.1 years (range 0.4-15.1 years) of follow-up time, 143 second breast cancer events occurred. Characteristics of the second events according to surgical treatment group and radiation are described in Table 2 . The second events were fairly evenly split between ipsilateral and contralateral events (52 vs. 48 % of those with known laterality), and in situ and invasive events (52 vs. 48 % of those with known stage). The majority of second events among women with an ipsilateral mastectomy were in the contralateral breast, whereas ipsilateral events were more common among women treated with BCS without radiation. Second events were evenly split between ipsilateral and contralateral among women treated with BCS and radiation. There were no second events experienced among women who were treated with bilateral mastectomy. Figure 3a displays the Kaplan-Meier curve for DFS among the DCIS cohort. DFS according to treatment type is shown in Fig. 3b and 5-year DFS rates are displayed in Table 3 . The overall 5-year DFS rate for the cohort was 94.5 % (95 % CI 93.2-95.5 %), and ranged from 87 % for women treated with BCS without radiation to 100 % for women undergoing a bilateral mastectomy. Overall 5-year DFS was similar among women undergoing ipsilateral mastectomy (95.6 %) and BCS with radiation (94.8 %). Differences in overall DFS by treatment were driven mainly by variation in rates of ipsilateral events. Five-year DFS for contralateral events was above 96 % regardless of treatment type.
Multivariable hazard ratios for second events are displayed in Table 4 . Compared to women treated with ipsilateral mastectomy, the risk of a second event for women treated with BCS without radiation was more than twice as high (HR 2.66, 95 % CI 1.58-4.46). The addition of radiation to BCS was associated with a 41 % reduction in risk of second events (HR 0.59, 95 % CI 0.38-0.92; data not shown). Compared to women treated with ipsilateral mastectomy, the risk of a second event was higher among the group of women treated with BCS and radiation (HR = 1.61; 95 % CI 1.07-2.43; Table 4 ). Within this group, risk of a second breast cancer event was similar according to tamoxifen use, although the hazard ratio suggested a potential benefit (HR 0.70; 95 % CI 0.41-1.19; data not shown). The risk of a second event among women treated with BCS, radiation, and tamoxifen was comparable to that of women treated with ipsilateral mastectomy (HR 1.20, 95 % CI 0.71-2.02; Table 4 ). Overall, models that adjusted only for age and year of diagnosis were similar to fully adjusted models; although hazard ratios were slightly attenuated, the estimates did not change meaningfully and relevant associations remained significant before and after complete adjustment (data not shown). Repeating the multivariable analysis using only those women with complete tumor size and grade information (approximately 30 % of the study population) and again without adjustment for tumor size or grade did not meaningfully affect the results. Point estimates for the hazard ratios remained stable and confidence intervals widened as would be expected. Likewise, the addition of BMI to the multivariable model did not have a substantive impact on the findings.
Discussion
In this large prospective population-based cohort study, approximately 95 % of subjects had not experienced a second breast cancer diagnosis at 5 years after diagnosis. Five-year survival rates for women undergoing BCS with radiation (94.8 %) were higher than for women treated with BCS without radiation (87.0 %). Women who received tamoxifen in addition to BCS and radiation had comparable 5-year DFS (95.0 %) to women receiving ipsilateral mastectomy (95.6 %).
Much of what is known about DCIS disease progression comes from randomized trials comparing various treatment protocols [10] [11] [12] [13] [18] [19] [20] [21] [22] [23] . Our study evaluated the survival experience of women with DCIS in the general population. We found that the effectiveness of radiation therapy and tamoxifen in reducing risk of second events was comparable to the efficacy observed in randomized trials. A meta- analysis of randomized trials estimated that the addition of radiation therapy to BCS reduces the risk of second events by 41 % [24] , which is identical to the reduction in risk of second events we observed for women treated with BCS and radiation compared to women treated with BCS without radiation. These results are also comparable to previous population-based observational studies of BCS with and without radiation [25] [26] [27] . Randomized trials have also demonstrated that the addition of tamoxifen to BCS reduces risk of second events by about 30 % [10, 11, 28] . We observed a similar effect among women treated with BCS plus radiation, although the result was not statistically significant. Tamoxifen did not appear to provide a benefit for women treated with BCS without radiation in our study, though this result was based on limited numbers (total of 28 second events). In a previous population-based study of tamoxifen, Warren et al. [26] found that tamoxifen use was not associated with risk of an ipsilateral recurrence among DCIS cases who were treated with BCS. Further study is needed to more precisely establish the effectiveness of tamoxifen outside of clinical trials, with particular need to evaluate adherence to treatment and the impact of duration of treatment on DFS.
The absolute 5-year DFS rates observed in our study are substantially higher than those observed in previous randomized trials and population-based studies of cases diagnosed prior to the year 2000. The meta-analysis of randomized trials of radiation therapy (covering cases diagnosed between 1985 and 1998) estimated 5-year overall DFS of 79.3 % for women treated with lumpectomy only and 88.7 % for women treated with lumpectomy plus radiation [24] . The higher overall DFS in our study likely reflects a number of differences in the study populations, their DCIS detection, and treatments. Notably, about 40 % of the women receiving BCS in our study were also taking tamoxifen. However, for women in our study receiving tamoxifen and radiation following BCS, overall 5-year DFS was 95.0 %, which is still higher than the 91.2 % 5-year overall DFS observed in the NASBP-24 trial of tamoxifen in addition to radiation therapy [22] .
The elevated DFS rates among women receiving BSC in our study likely reflect the temporal trends toward increased sensitivity of mammography and the improvements in surgical margins during BCS. This phenomenon is supported by a study of DCIS cases in three health maintenance organizations within the Cancer Research Network [29] . Among cases treated with BCS, overall 5-year DFS improved from 81.5 % for cases diagnosed in 1990-1991 to 89 % in 1998-1999. The authors determined that increasing use of radiation and tamoxifen over time could only explain about one-third of the improvement in DFS. They observed that patients diagnosed in later years were less likely to have involved surgical margins, and proposed that this likely contributed to decreased recurrence rates. Our results provide evidence that DFS rates following BCS for DCIS are continuing to increase.
No randomized trials have compared BCS to mastectomy for the treatment of DCIS, yet previous observational studies have indicated that women undergoing BCS are more likely to experience a recurrence [30] [31] [32] [33] . In a recent analysis of DCIS cases diagnosed in western New York and Detroit between 1985 and 2000, the cumulative incidence of ipsilateral events at 5 years was 5.5 % for women treated with BCS plus radiation and 1 % for women treated with mastectomy [32] . In our study of cases diagnosed between 1995 and 2006, this gap had narrowed to 3.1 versus 1.3 %, respectively. These results suggest that in community practice, BCS with adjuvant therapies now provides very similar DFS to ipsilateral mastectomy. Like other population-based studies, our study has limitations that must be considered. Although participation in our study by eligible women was high, it is possible that women in active treatment for a breast cancer recurrence may have differentially chosen not to participate. Our multiple rounds of follow-up interviews and high participation rates ameliorate this concern somewhat. The high DFS observed in our study resulted in low power to detect differences in stratified analyses. We relied on self-report of treatments received and second event diagnoses. Medical record validation indicated excellent reliability of selfreported second events (91 % confirmed). Thus, the inclusion of second event diagnoses which could not be confirmed via medical records is not likely to have introduced substantial bias to our results. Sensitivity analyses indicated that the associations between each treatment and DFS were not meaningfully changed when the unconfirmed second events were excluded from the analyses.
The effectiveness of BCS for DCIS varies according to margin status [32] and it is known that the threshold for adequate margins varies widely in community practice, resulting in highly variable re-excision rates [34] . We were unable to examine the role of margin status or other surgical practice factors in our results. We were also unable to control for estrogen and progesterone receptor status, as this data was unavailable for the index DCIS diagnoses. In addition, we had incomplete data on covariates such as tumor size and grade. To enable statistically efficient use of the data and avoid bias by excluding cases with missing information, we used multiple imputation to estimate missing data for these covariates [35] .
Our results are based on outcomes over an average of 7.1 years (range 0.4-15.1 years) of follow-up. It is possible that different patterns in DFS by treatment may emerge with longer follow-up. However, prior studies of DCIS outcomes according to treatment have generally reported similar proportional differences at 5 and 10 years of follow-up [10, 32] . WISC study subjects will continue to be followed to compare long-term outcomes among women treated with mastectomy and BCS with adjuvant therapies. Finally, we note that the study population was predominantly white (95 %), reflecting the racial distribution of breast cancer cases diagnosed in Wisconsin. Studies in more racially diverse populations will be needed to assess the generalizability of these results.
There are approximately 500,000 women alive today in the United States with a diagnosis of DCIS [36] . These women face an increased risk of developing an invasive breast cancer diagnosis [37] and may suffer reductions in their health-related quality of life due to side effects of treatments and the psychological effects of a cancer diagnosis [38] . Our findings provide evidence regarding the comparative effectiveness of current treatments for DCIS in community practice. The results suggest that BCS with radiation and tamoxifen can provide DFS rates comparable to that of ipsilateral mastectomy.
